Gene Network Sciences Licenses Ariadne Genomics’ PathwayStudio® Central
Ariadne Genomics, Inc., today announced that Gene Network Sciences (GNS) has licensed its PathwayStudio® Central software for molecular network modeling and pathway analysis. GNS will use PathwayStudio Central to better interpret in the context of known biology the drug-specific protein and gene networks discovered by the GNS technology platform.
“PathwayStudio Central is an efficient and effective tool to help integrate the latest pathway-related knowledge scattered throughout scientific publications with our pre-clinical and clinical models,” said Jeffrey Fox, Ph.D., vice president of research of GNS.
PathwayStudio Central enables life science researchers to interpret their own discoveries in the context of biological pathways and gene regulation networks. They can identify relationships among proteins, small molecules, cell processes and treatments, reconstruct pathways from microarray and proteomics data, identify biomarkers, and model drug responses. The software comes with ResNet™ database of 500,000+ functional relationships and MedScan™ tool for automatic extraction of information from scientific literature.
More information about PathwayStudio Central, or a 20 day fully functional product trial, can be found on the Ariadne Genomics website www.ariadnegenomics.com .
About Ariadne Genomics
Ariadne Genomics develops systems biology tools for life science research: PathwayStudio® Central client-server and PathwayAssist™ desktop pathway analysis software; MedScan™ Text-to-Knowledge Suite, an automated scientific text processing tool; ResNet™ molecular networks database, created by extraction of biological facts from the entire PubMed, and Seqware™ personal sequence data management platform. More on Ariadne Genomics please find at www.ariadnegenomics.com .
About Gene Network Sciences
Founded in 2000, Gene Network Sciences ( www.gnsbiotech.com ) is a privately held biosimulation company headquartered in Ithaca, New York. GNS creates cell and organ-level computer models able to simulate the clinical performance of drugs and drug candidates. By predicting how and why specific compounds impact human biology, GNS technology increases clinical trial success rates and helps bring better drugs to market faster.
